20Jul 2017

FACTOR V LEIDEN G1691A AND PROTHROMBIN G20210A POLYMORPHISMS IN GEORGIAN ARTERIAL THROMBOSIS PATIENTS.

  • Batumi Shota Rustaveli State University, Faculty of Natural Sciences and Health Care. Batumi, Georgia.
  • UCIBIO, REQUIMTE and Faculty of Pharmacy, University of Porto, Porto, Portugal.
  • Tbilisi State Medical University, faculty of medicine , department of internal medicine, Tbilisi, Georgia.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Thrombosis plays a crucial role in the pathogenesis of acute myocardial infarction, stroke and venous thrombosis. Factor V Leiden (FVL) and prothrombin (PT) G20210A polymorphisms are the most frequent causes of inherited thrombophilia. In this work, we aimed to evaluate the prevalence of FVL and PT G20210A polymorphisms in a Georgian cohort of patients and healthy individuals, and its association with arterial thrombosis. This study involved 214 individuals, 101 arterial thrombosis patients (71.3% males; 66.3 +/- 12.1 years old) and 113 healthy control subjects (67.3% males; 56.6 +/-11.3 years old). Genomic DNA was extracted from a dry blood spot on Whatman paper. Polymerase chain reaction was performed in order to determine the two genetic markers of thrombosis risk: FVL (G1691A) and PT G20210A polymorphisms. The frequency of FVL allele polymorphism in the control group was 0.9%, which corresponds to a heterozygous stage frequency of 1.8%. In the patient group, an allelic frequency of 2% was found, which corresponds to the presence of 4% of heterozygous individuals. The frequency of heterozygosity for the PT G20210A polymorphism was 4.4% in the control group, which corresponds to an estimated allelic frequency of 2.2%. In the patient group, a frequency of heterozygosity of 3% was found, which corresponds to an estimated allelic frequency of 1.5%. Homozygosity for FVL and PT G20210A polymorphisms was not found in either group. Our results suggests that FVL could be associated with arterial thrombosis as a double prevalence was found in the patient group when compared with the control group, although no significant differences were found. Moreover, our results also showed that the PTG20210A polymorphism seems to not be associated with arterial thrombosis in the Georgian population. More studies are required with a bigger sample in order to draw definitive conclusions.


  1. United Nations. (2015). World Population Ageing. Retrieved fromhttp://www.unpopulation.org
  2. The Ministry of Labour Health and Social Affairs of Georgia. (2014). Report for the National Voluntary Presentation at the ECOSOC 2014 Annual Ministerial Review. Retrieved from http://www.un.org/en/ecosoc/newfunct/pdf14/georgia_nr.pdf
  3. Vogeli, C., Shields, A.E., Lee, T.A., Gibson, T.B., Marder, W.D., Weiss, K.B., Blumenthal, D. (2007). Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J Gen Intern Med, 22 (Suppl 3), 391?395.
  4. Beaglehole, R., Bonita, R. (2008). Global public health: a scorecard. Lancet, 372,1988-1996.
  5. The Ministry of Labour Health and Social Affairs of Georgia (2009)National report. Retrieved from greenadvocacy.net/photos/3296-National%20Report%202009.pdf
  6. Egeberg, O. (1967). Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorr, 13, 516-530.
  7. Nakashima, M.O., Rogers, H.J. (2014). Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. Blood Res, 49(2), 85?94.
  8. Friedline, J.A., Ahmad, E., Garcia, D., Blue, D., Ceniza, N., Mattson, J.C., Crisan, D. (2001). Combined factor V Leiden and prothrombin genotyping in patients presenting with thromboembolic episodes. Arch Pathol Lab Med, 125(1),105-111.
  9. Angelini, A., Di Febbo, C., Rullo, A., Di Ilio, C., Cuccurullo, F., Porreca, E. (2002). New method for the extraction of DNA from white blood cells forthe detection of common genetic variants associated with thrombophilia. PathophysiolHaemostThromb, 32, 180-183.
  10. Lowe, G.D.O., Rumley, A., Woodward, M., et al. (1997). Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol, 97, 775?784.
  11. Nieto, F.J. (1999). Cardiovascular disease and risk factor epidemiology: a look back at the epidemic of the 20th century. Am J Pub Health, 89, 292?294.
  12. Rumley, A., Emberson, J.R., Wannamethee, S.G., et al. (2006). Effects of older age on fibrin D-dimer, C-reactive protein and other hemostatic and inflammatory variables in men aged 60?79 years. J ThrombHaemost, 4, 982?987.
  13. Arboix, A. (2015). Cardiovascular risk factors for acute stroke: Risk profiles in the different subtypes of ischemic stroke. World J Clin Cases, 3(5), 418?429.
  14. Dahlback, B., Carlsson, M., Svensson, P.J. (1993). Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. ProcNatlAcadSci, 90, 1004?1008.
  15. Bertina, R.M., Koeleman, B.P., Koster, T., Rosendaal, F.R., Dirven, R.J., de Ronde, H., van der Velden, P.A., Reitsma, P.H. (1994). Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 369, 64-67.
  16. Jadaon, M.M, (2011). Epidemiology of activated protein C resistance and factor V leiden mutation in the Mediterranean region. Mediterr J Hematol Infect Dis, 3, e2011037.
  17. Kalkanli, S., Ayyildiz, O., Tiftik, N., Batun, S., Isikdogan, A., Ince, H., Tekes, S., Muftuoglu, E. (2006). Factor V Leiden mutation in venous thrombosis in southeast Turkey. Angiology, 57, 193-196.
  18. Poort, S.R., Rosendaal, F.R., Reitsma, P.H., Bertina, R.M. (1996). A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood, 88, 3698-3703.
  19. Koeleman, B.P., Reitsma, P.H., Allaart, C.F., Bertina, R.M. (1994). Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood, 84, 1031-1035.
  20. Mehrez, M. (2011). Jadaon Epidemiology of Prothrombin G20210A Mutation in the Mediterranean Region. Mediterr J Hematol Infect Dis, 3, e2011054.

[Garakanidze Sopio, Elisio Costa, Elsa Bronze-Rocha, Alice Santos-Silva, Nikolaishvili Giorgi, Glonti Salome, Kakauridze Nona and Koridze Marina. (2017); FACTOR V LEIDEN G1691A AND PROTHROMBIN G20210A POLYMORPHISMS IN GEORGIAN ARTERIAL THROMBOSIS PATIENTS. Int. J. of Adv. Res. 5 (Jul). 1171-1175] (ISSN 2320-5407). www.journalijar.com


Garakanidze Sopio1, Elísio Costa2, Elsa Bronze-Rocha2, Alice


DOI:


Article DOI: 10.21474/IJAR01/4825      
DOI URL: http://dx.doi.org/10.21474/IJAR01/4825